NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease
Sara Mastaglio(Laboratoire d’immunologie intégrative du cancer), Pietro Genovese(IRCCS Ospedale San Raffaele), Zulma Magnani(Laboratoire d’immunologie intégrative du cancer), Eliana Ruggiero(Laboratoire d’immunologie intégrative du cancer), Elisa Landoni(Laboratoire d’immunologie intégrative du cancer), Barbara Camisa(Laboratoire d’immunologie intégrative du cancer), Giulia Schiroli(Vita-Salute San Raffaele University), Elena Provasi(Laboratoire d’immunologie intégrative du cancer), Angelo Lombardo(Vita-Salute San Raffaele University), Andreas Reik(Sangamo BioSciences (United States)), Nicoletta Cieri(Laboratoire d’immunologie intégrative du cancer), Martina Rocchi, Giacomo Oliveira(Laboratoire d’immunologie intégrative du cancer), Giulia Escobar(Vita-Salute San Raffaele University), Monica Casucci(Society for Immunotherapy of Cancer), Bernhard Gentner(IRCCS Ospedale San Raffaele), Antonello E. Spinelli, Anna Mondino, Attilio Bondanza(Society for Immunotherapy of Cancer), Luca Vago(Gene Therapy Laboratory), Maurilio Ponzoni(Vita-Salute San Raffaele University), Fabio Ciceri(Vita-Salute San Raffaele University), Michael C. Holmes(Sangamo BioSciences (United States)), Luigi Naldini(Vita-Salute San Raffaele University), Chiara Bonini(Vita-Salute San Raffaele University)
Cited by 83Open Access
Abstract
targets; however, although TR cells proved highly alloreactive, SE cells showed a favorable safety profile. Accordingly, when infused in NSG mice previously engrafted with myeloma, SE cells mediated tumor rejection without inducing xenogeneic graft-versus-host disease, thus resulting in significantly higher survival than that observed in mice treated with TR cells. Overall, single TCR gene editing represents a clinically feasible approach that is able to increase the safety and efficacy of cancer adoptive immunotherapy.